Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron‐emission tomography with18F‐fluorodeoxyglucose-Reference-Cited by-同舟云学术

Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron‐emission tomography with18F‐fluorodeoxyglucose

Published:2004-07 Issue:7 Volume:80 Page:529-539
ISSN:0955-3002
Container-title:International Journal of Radiation Biology
language:en
Short-container-title:International Journal of Radiation Biology

Author:

De Wit M.,Raabe A.,Seegers B.,Buchert R.,Beck‐Bornholdt H.‐P.,Alberti W.,Hossfeld D. K.

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Link

http://www.tandfonline.com/doi/pdf/10.1080/09553000410001723875

Reference20 articles.

1. Computertomographie und F-18-FDG-Positronen-Emissions-Tomographie im Staging maligner Lymphome: ein Vergleich

2. Diagnostic Efficacy of PET-FDG Imaging in Solitary Pulmonary Nodules

3. Depopulation and repopulation of the R1H rhabdomyosarcoma of the rat after X-irradiation

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas;PET Clinics;2015-07

2. Compressive Osseointegration Into a Custom Acetabular Implant Masquerading as Tumor Recurrence: A Case Report;Clinical Orthopaedics & Related Research;2013-03

3. Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy;International Journal of Radiation Biology;2009-01

4. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation;International Journal of Radiation Biology;2009-01

5. Potential Time Benefit in the Assessment of Recurrent Rat Rhabdomyosarcoma Using Positron Emission Tomography (PET) with 18Fluorodeoxyglucose Depends on Therapy-Specific Growth Delay;Strahlentherapie und Onkologie;2006-10